Guardant Health, Inc. (NASDAQ:GH) Stock Position Reduced by Candriam S.C.A.

Candriam S.C.A. lessened its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 3.7% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 352,492 shares of the company’s stock after selling 13,653 shares during the quarter. Candriam S.C.A.’s holdings in Guardant Health were worth $10,769,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Lord Abbett & CO. LLC bought a new position in Guardant Health during the 3rd quarter worth approximately $15,624,000. Guyasuta Investment Advisors Inc. bought a new position in Guardant Health during the 4th quarter worth approximately $206,000. Cerity Partners LLC raised its position in shares of Guardant Health by 54.6% during the 3rd quarter. Cerity Partners LLC now owns 195,008 shares of the company’s stock worth $4,473,000 after purchasing an additional 68,883 shares during the period. Geode Capital Management LLC raised its position in shares of Guardant Health by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company’s stock worth $64,754,000 after purchasing an additional 29,686 shares during the period. Finally, Entropy Technologies LP acquired a new stake in shares of Guardant Health during the 4th quarter worth approximately $377,000. Institutional investors own 92.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. The Goldman Sachs Group increased their price target on Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Canaccord Genuity Group increased their price target on Guardant Health from $42.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday, February 24th. Piper Sandler increased their price target on Guardant Health from $34.00 to $50.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Scotiabank increased their price target on Guardant Health from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a research report on Monday, February 24th. Finally, JPMorgan Chase & Co. increased their price target on Guardant Health from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Twenty equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $48.40.

Guardant Health Stock Performance

Shares of GH stock opened at $39.32 on Friday. Guardant Health, Inc. has a 1 year low of $15.81 and a 1 year high of $50.89. The stock has a market cap of $4.85 billion, a PE ratio of -11.04 and a beta of 1.50. The business’s fifty day moving average is $41.88 and its 200-day moving average is $32.32.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The firm had revenue of $201.81 million for the quarter, compared to analyst estimates of $192.50 million. Equities research analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Insider Transactions at Guardant Health

In other news, Director Musa Tariq sold 2,320 shares of the firm’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $35.00, for a total transaction of $81,200.00. Following the completion of the sale, the director now directly owns 2,676 shares of the company’s stock, valued at $93,660. This trade represents a 46.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold a total of 2,668 shares of company stock valued at $95,208 in the last three months. 5.50% of the stock is currently owned by corporate insiders.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.